Novo Nordisk ... s growth disorders in a Phase III trial. The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for gestational age ...

Novo Nordisk reports phase 3 data showing weekly Sogroya matched or outperformed daily hormone therapy in multiple pediatric growth disorders.

Results from the Phase III REAL8 basket study show that Novo Nordisk’s Sogroya (somapacitan) demonstrated significant efficacy and was well-tolerated in children with growth disorders, including those ...

Novo Nordisk A/S (NYSE ... in four different but related growth disorder indications, including small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS), and idiopathic short ...

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin (somatropin) in children’s growth disorders in a Phase III trial. The Danish ...

Novo Nordisk reported positive data ... as well as compared to lower doses of a daily growth hormone in children born small for gestational age. Sogroya also worked at least as well in children ...

Superiority was achieved for once-weekly somapacitan versus daily growth hormone in children with NS 2, as well as compared to lower doses of daily growth hormone in children born SGA 1.

Sogroya was more effective at stimulating growth than Norditropin, and the newer drug also outperformed lower doses of the once-daily product in children born with SGA. According to Novo Nordisk ...